Glycyrrhizin can inhibit the replication of SARSCoV-2
TIME:2020-05-08 HITS:968
[Peking University team disclosed heavy research results: #Glycyrrhizin can inhibit the replication of SARSCoV-2#] According to the Beijing Daily, the team of Xie Zhengwei of Peking University and the team of Qin Zhengfeng of the Academy of Military Medical Sciences published the title of "An artificial "Intelligence system reveals liquiritin inhibits SARSCoV-2 by mimicking type I interferon" (artificial intelligence system shows that glycyrrhizin inhibits SARSCoV-2 by mimicking type I interferon). The study found that glycyrrhizin, one of the main components of licorice, can inhibit the replication of SARS-CoV-2 in Vero cells through its self-developed artificial intelligence drug efficacy prediction system. The EC50 is 2.39 μM. The changes in the transcriptome revealed the potential antiviral mechanism of glycyrrhizin, and evaluated the safety of glycyrrhizin at the mouse level, which laid the foundation for its patentability. Glycyrrhizin is one of the main flavonoid compounds in licorice and one of the main components of compound licorice tablets. It has antioxidant, antidepressant, nerve protection, anti-inflammatory and other physiological activities. It has been reported that patients with severe COVID-19 often suffer from cytokine storm syndrome (CSS), and glycyrrhizin has multiple antiviral and anti-inflammatory activities. It has multiple advantages in the treatment of novel coronavirus pneumonia and is expected to develop into anti-SARS- CoV-2's new drug also prepares candidate drug reserves for the future prevention and control of infectious diseases of coronavirus.